Á¾¾ç¸é¿ªÄ¡·á: Áß¼¼ ¾ÏÈæ½Ã´ë¿¡¼ ¸£³×»ó½º½Ã´ë·Î
Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages
´ëÇѳ»°úÇÐȸÁö 2014³â 87±Ç 3È£ p.284 ~ p.295
ÀÌ´ëÈ£(Lee Dae-Ho) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø Á¾¾ç³»°ú
Abstract
Cancer immunotherapy has come a long way since William Coley observed that a mixture of killed bacteria, or Coley¡¯s toxin, induced tumor regression. However, enthusiasm for cancer immunotherapy has changed to skepticism over recent decades due to its lack of efficacy, inconsistency, and significant toxicity. Of course, much of that skepticism was the result of a lack of understanding of the immune system. The recent expansion of our understanding of immunity and immune system and the success of new cancer immunotherapies has raised hope that we can treat cancer effectively via immunotherapy or combination approach using immunotherapy and other cancer therapies. Indeed, there is no doubt that cancer immunotherapy is experiencing a renaissance. Here, I will briefly review the current status of various immunotherapies, including cytokine therapy, antibody therapy, cancer vaccines, and adoptive cell therapy, and then I will summarize the results of recent clinical trials using anti-immune checkpoint monoclonal antibodies.
Å°¿öµå
Á¾¾ç, ¸é¿ªÄ¡·á, Ç׸鿪°Ë¹®Ç×ü
Cancer, Immunotherapy, Anti-immune checkpoint antibody
KMID :
0882420140870030284
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
This article reviewed the current status of various immunotherapies, including cytokine therapy, antibody therapy, cancer vaccines, and adoptive cell therapy, and summarized the results of recent clinical trials using anti-immune checkpoint monoclonal antibodies.